Abstract:Objectives Multiple sclerosis (MS) comprises a chronic, neurodegenerative, and inflammatory illness of the central nervous system that affects 2.8 million people worldwide. MS is only treatable, and to this direction, the disease armamentarium has been significantly enriched with new agents, albeit with burgeoning costs and engulfed by uncertainty. The scope of this review is to assess the efficiency of MS agents. Methods We performed a systematic literature review, spanning from 2000 to 2023 on adult patients with any form of MS, receiving any MS indicated modality and whose outcome was ICUR and ICER. The methodological quality of the studies was assessed with the QHES tool. Results We identified 57 studies that met the inclusion criteria. Studies were hailing from 20 countries and a multitude of methodological approaches were documented across several types of MS. A substantial level of divergence regarding results was noted. Country setting, study perspective (social vs healthcare) the selection of the benchmark treatment, data extrapolation beyond the reported timeframe of the trial and time horizon of the model exerted a substantial impact on the results. Dimethyl fumarate was consistently interrelated with a positive cost-effectiveness ratio. The same applies for fampridine, while Cladribine was proved to be a dominating agent. Ocrelizumab also evinced efficiency. The same applies for the early data of Siponimod and ofatumumab, however the breadth of their studies lags compares to other agents, and these results have to be further corroborated. On the contrary Interferons demonstrated a non-efficient profile and their use as a comparative benchmark arm brought about several complications regarding the incremental financial aspect of economic evaluations, since they are commonly used as the benchmark. The results of fingolimod and natalizumab studies are embroiled in uncertainty. Moreover, the efficiency factor was positively correlated by earlier access of patients to these products, rather than delayed one. Result discrepancies among the same country were also imputed to the adopted utility and disutility values and the methodological approach for data extrapolation. Results were sensitive to an array of factors. Among them, the effectiveness of the products, coupled with the cost of the agents emerged as the most important drivers. Uncertainty was further compounded by several other parameters such as discounting, efficacy waning, horizon of the study, disability base rate and utility of the patients. We also outlined that the efficiency of product is pertinent to the disease type. Results such as dominance must be interpreted with caution since in certain cases a dominating agent was proved to be as such by capitalizing on marginal incremental health gains, compared to the standard comparative treatment. Conclusions An increasing body of evidence consisting of economic evaluations for MS was retrieved. These studies exhibited high quality, however, the consistency regarding results was impaired.

Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption

Improving quality, affordability, and equity of multiple sclerosis care

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis

Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany

Old and New Strategies in the Treatment of Pediatric Multiple Sclerosis: A Personal View for a New Treatment Approach

The Multiple Sclerosis Treatment Optimization Program

Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis

Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations

Untackling the economics of Multiple Sclerosis: a systematic review of economic evaluations of disease-modifying therapies indicated for Multiple Sclerosis

Evaluation of a Quality Measure for Multiple Sclerosis Care: Disease-Modifying Therapy Initiation at the University of North Carolina's Outpatient Neurology Clinic

Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey

Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study

Early Aggressive Treatment Approaches for Multiple Sclerosis

Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis

Multiple Sclerosis: Systemic Challenges to Cost-Effective Care

Insights for Healthcare Providers on Shared Decision-Making in Multiple Sclerosis: A Narrative Review

Data-driven risk/benefit estimator for multiple sclerosis therapies

Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis

Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis

MS care: integrating advanced therapies and holistic management

Escalating to medium‐ versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosis